ImmunoMet Lands $5,200,000 Series A Financing
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=6aa9f180-2183-4367-b809-0e2f429f6da0 - Date
3/9/2016 - Company Name
ImmunoMet - Mailing Address
2450 Holcombe Blvd. Houston, TX 77021 USA - Company Description
ImmunoMet Therapeutics is a development-stage biotechnology company, focused on the development of innovative oncology products to improve the quality of life and make a meaningful difference in the lives of cancer patients. - Website
http://www.immunomet.com - Transaction Type
Venture Equity - Transaction Amount
$5,200,000 - Transaction Round
Series A - Proceeds Purposes
The primary use of these proceeds will be to fund the Company’s research and clinical development programs, establish its worldwide headquarters in Houston, TX, and for general corporate purposes. - M&A Terms
- Venture Investor
Mirae Asset Venture Investment - Venture Investor
Undisclosed
